Soligenix, Inc. (SNGX)
| Previous close | 0.3930 |
| Open | 0.3856 |
| Bid | 0.0000 x 0 |
| Ask | 0.3672 x 300 |
| Day's range | 0.3447 - 0.3876 |
| 52-week range | 0.3447 - 2.0000 |
| Volume | |
| Avg. volume | 2,729,719 |
| Market cap | 5.596M |
| Beta (5Y monthly) | 1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7900 |
| Earnings date | 19 Aug 2024 - 23 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.50 |
PR NewswireSoligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote "FOR" a Reverse Stock Split. The Company and its Board of Directors believe it is important to maintain the listing of the Common Stock on The Nasdaq Capital Market ("Nasdaq"). "Failure to maintain our listing on Nasdaq and meet Nasdaq's listing
GlobeNewswirePRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an in-depth interview with Dr. Christopher Schaber, President and Chief Executive Officer of Soligenix, Inc. (Nasdaq: SNGX). The late-stage biopharmaceutical company is advancing a broad pipeline of therapeutic and vaccine candidates across its two business segments, emphasizing its strategic focus on diversified drug development. Soligenix has recently achieved success in its first Phase 3 clinical trial of HyBryte™ (synthetic
- PR Newswire
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Professor Axel Lehrer, University of Hawaiʽi at Mānoa (UHM), will be presenting key data from the Company's thermostable vaccine technology platform developed in collaboration with UHM, including results from the filovirus vaccine candidates for both Sudan ebolavirus (
